Automated tool for diabetic retinopathy screening
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial is testing an automated tool that helps screen for diabetic retinopathy, a complication of diabetes that affects the eyes. The goal is to see if the tool can accurately detect the condition, which may help with early treatment and prevent vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 22 years old.
- You have diabetes or diabetic retinopathy.
- You can understand the study and sign a consent form.
- You have not had laser treatment or injections in your eyes.
- You have not had eye surgery (except simple cataract surgery).
- You are not pregnant and are willing to have your eyes dilated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an AI program called DRISTi to screen for diabetic eye disease by taking pictures of the back of your eye. It's designed for adults with diabetes who haven't had major eye treatments or vision loss.
This trial uses artificial intelligence to analyze eye images and help doctors diagnose eye diseases. It looks at images from routine care to train and test the AI system.
This study uses an artificial intelligence (AI) tool to analyze eye images in people with type 2 diabetes. The goal is to see if the AI can help detect early signs of diabetic eye disease, so you can get the right care sooner.
This trial tests if an AI tool can help detect diabetic retinopathy and age-related macular degeneration in older adults visiting family medicine or geriatric clinics. It aims to catch these eye conditions early, before they cause vision loss.
This trial is testing a new, intelligent way to screen for and diagnose eye diseases using a mobile device. It may help catch eye problems early, especially in people who have trouble getting to a doctor.
This study tests an AI platform that checks for diabetic retinopathy, a common eye problem in people with diabetes. It aims to see if the AI can spot signs of damage early, so you can get treatment sooner.
Hear when a new Diabetic Retinopathy (DR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.